I still can't find any official confirmation of the number of AIDS2014 delegates lost on the flight. But Nature News & Comment has this about Dr. Joep Lange: Scientist killed on MH17 brought HIV therapy to the poor. Excerpt:
“Why is it,” Joep Lange told an International AIDS Conference in the early 2000s, “that we are always talking about the problem of drug distribution, when there is virtually no place in Africa where one cannot get a cold beer or a cold Coca-Cola.”
The Dutch clinical virologist — who was among the 298 passengers who died in the downing of a Malaysia Airlines flight on 17 July, and one of many headed to the 20th International AIDS Conference in Melbourne, Australia — worked since the early 1990s to deliver HIV drugs deep into the world’s poorest countries. Between 2002 and 2004, he served as president of the International AIDS Society, which organizes the annual meeting, among the largest and most important in the HIV research community.
In 1996, Lange co-founded a clinical-trial network in Thailand to test the feasibility of providing antiretroviral drugs to HIV patients in low- and middle-income countries. The HIV Netherlands Australia Thailand Research Collaboration, known as HIV-NAT, has since completed 68 studies and was among the earliest research efforts to establish that antiretroviral drugs that attack HIV can be cheaply and effectively delivered in resource-poor settings such as Thailand.
Lange was a clinical virologist at the University of Amsterdam. His research explored HIV drug resistance, the role of antiretroviral drugs in preventing transmission from mother to child and other issues related to managing HIV/AIDS. His research helped to establish the safety and effectiveness of treating patients with multiple antiviral drugs, which is now standard. He co-founded the journal Antiviral Therapy and advised several drug companies on antivirals.
In 2000, Lange helped to launch a not-for-profit organization in Amsterdam called the PharmAccess Foundation to bring antiretroviral drugs to sub-Saharan Africa, where the HIV epidemic was in full swing and most patients still went untreated.
The effort started with a modest, yet novel idea: treating employees and their dependents of the Dutch beer-maker Heineken (an early supporter of PharmAccess) in sub-Saharan Africa. The foundation has since broadened its reach, creating a fund that subsidizes health insurance (which pays for antiretroviral drugs) for about 100,000 people in Nigeria, Tanzania and Kenya.